Therapy Areas: Allergy
IgGenix presents IGNX001 data at 2024 ASCIA
3 September 2024 - IgGenix Inc, a US-based preclinical antibody discovery and development company, announced on Monday that it has presented data on its lead candidate, IGNX001, an IgG4 monoclonal ant...
EURneffy approved in EU for needle-free anaphylaxis treatment
26 August 2024 - Biopharmaceutical company ARS Pharmaceuticals Inc (Nasdaq:SPRY) announced on Monday that the European Commission has approved EURneffy (adrenaline nasal spray) for the emergency treat...
Anivive Lifesciences receives new contract from National Institute of Allergy and Infectious Diseases
5 August 2024 - California-based pet pharmaceutical company at the intersection of biotech, AI, software, and veterinary medicine Anivive Lifesciences Inc announced on Friday that it has received a ne...
The National Institute of Allergy and Infectious Diseases provides up to USD3m malaria vaccine development grant to Versatope Therapeutics
30 July 2024 - US-based biotechnology company developing vaccines and immuno-therapeutics Versatope Therapeutics Incorporated announced on Monday that the National Institute of Allergy and Infectious ...
Crossject secures EUR6.9m French government grant to advance ZENEO Epinephrine
10 July 2024 - Pharmaceutical company Crossject (Euronext Growth Paris:ALCJ) announced on Wednesday that it has received EUR6.9m in public funding from the French government's France 2030 plan to...
Allergy Therapeutics initiates subcutaneous dosing in peanut allergic patients for VLP Peanut PROTECT trial
12 March 2024 - Allergy Therapeutics plc (AIM: AGY), a UK-based biotechnology company that specialises in allergy vaccines, announced on Tueday that it has commenced subcutaneous dosing of peanut alle...